Featuring an interview with Dr Jamie E Chaft, including the following topics:

• Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)
• Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)
• Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)
• Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)
• Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)
• Importance of clinical trials in the adjuvant setting (33:02)
• Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)
• Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)
• Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)
• Molecular analyses in the assessment and management of endometrial cancer (07:33)

CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

• Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
• - Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
• - Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
• - Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:

• Introduction (00:00)
• Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)
• Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)
• Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)
• Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)
• Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)

CME information and select publications

Featuring an interview with Dr Floor J Backes, including the following topics:

• Overview of the treatment landscape of endometrial cancer (00:00)
• Immunotherapy for advanced endometrial cancer (03:58)
• Contraindications for immunotherapy (18:15)
• PARP inhibitors for endometrial cancer (20:12)
• Management of localized endometrial cancer (28:23)
• Novel strategies under investigation for endometrial cancer (42:27)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (2:07)
• Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
• Currently Available ADCs for Gynecologic Cancer Management (26:37)
• Currently Available ADCs for Lung Cancer Management (44:07)
• Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
• Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
• Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Featuring an interview with Dr Rana R McKay, including the following topics:

• Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
• Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
• Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
• Takeaways from the Phase III EMBARK study (19:36)
• Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
• Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics:

• Overview of the current landscape of prostate cancer (0:00)
• Mechanism of action of androgen deprivation therapy (ADT) (3:51)
• Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18)
• Real-world evidence regarding the use of relugolix (12:27)
• Adverse event profile associated with ADT (18:34)
• Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who receives ADT at various timepoints of treatment and is currently on relugolix (21:46)
• Case: A man in his early 60s with high-risk locally advanced prostate cancer who receives various androgen receptor pathway inhibitors in addition to relugolix (28:06)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:

• Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
• Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
• Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
• Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
• Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics:

• Introduction (0:00)
• Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)
• Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)

CME information and select publications